respiratori
viral
infect
caus
substanti
burden
preval
tend
affect
vulner
children
elderli
peopl
live
develop
area
subsaharan
africa
southeast
asia
advent
molecular
techniqu
facilit
identif
respiratori
virus
patient
pneumonia
shed
light
commonli
virus
occur
patient
pneumonia
current
avail
diagnost
tool
viral
pathogen
often
identifi
bacteri
pathogen
communityacquir
pneumonia
larg
amount
effort
current
dedic
elucid
pathogen
respiratori
virus
interact
virus
bacteria
set
pneumonia
sinc
last
centuri
number
devast
pandem
outbreak
relat
respiratori
virus
occur
recent
grow
interest
develop
new
antivir
medic
respiratori
infect
articl
provid
overview
pneumonia
caus
influenza
respiratori
virus
practic
clinician
perspect
focu
adult
popul
human
influenza
rna
viru
belong
orthomyxovirida
famili
categor
type
b
c
base
nucleoprotein
matrix
protein
influenza
viru
subcategor
subtyp
base
hemagglutinin
neuraminidas
influenza
b
subcategor
byamagata
bvictoria
lineag
influenza
infect
caus
type
b
gene
mutat
influenza
undergo
everi
year
call
antigen
drift
respons
season
outbreak
convers
influenza
pandem
caus
antigen
shift
occur
new
hemagglutinin
neuraminidas
subtyp
acquir
communityacquir
respiratori
virus
rna
virus
except
adenoviru
human
bocaviru
dna
virus
paramyxovirida
famili
includ
respiratori
syncyti
viru
parainfluenza
human
metapneumoviru
distinct
featur
paramyxovirida
famili
virus
presenc
fusion
protein
fusion
protein
enabl
integr
viru
cell
membran
allow
introduct
viral
genom
cell
cytoplasm
potenti
target
vaccin
antivir
picornavirida
famili
viru
includ
enteroviru
human
rhinoviru
character
capsid
contain
viral
genom
capsid
larg
cleft
canyon
bind
adhes
molecul
cell
surfac
lead
eventu
entri
viral
genom
cell
capsid
adhes
molecul
potenti
target
antivir
tabl
systemat
review
includ
observ
studi
enrol
patient
communityacquir
pneumonia
underw
viral
polymeras
chain
reaction
test
pool
proport
patient
viral
infect
confid
interv
ci
studi
perform
inpati
set
viral
polymeras
chain
reaction
obtain
mostli
nasal
oropharyng
swab
studi
perform
outpati
set
proport
viral
infect
ci
pool
proport
viral
infect
ci
studi
lower
respiratori
sampl
obtain
half
patient
proport
dual
bacteri
viral
infect
ci
although
presenc
viral
infect
significantli
increas
risk
shortterm
death
patient
dual
bacterialvir
infect
twice
risk
death
compar
patient
without
dual
infect
import
note
identif
viral
pathogen
patient
pneumonia
necessarili
mean
viru
pathogen
effect
particularli
identif
via
nasopharyng
swab
fig
tabl
immunocompromis
patient
pneumonia
infect
respiratori
virus
exceedingli
common
surveil
studi
show
respiratori
viral
pathogen
identifi
close
third
hospit
patient
leukemia
hematopoiet
stem
cell
transplant
respiratori
symptom
pneumonia
occur
immunosuppress
patient
infect
respiratori
viral
pathogen
immunocompromis
patient
commonli
infect
respiratori
virus
caus
infect
immunocompet
patient
howev
virus
herpesvirida
famili
also
tend
caus
infect
immunocompromis
patient
exampl
earli
seri
patient
underw
allogen
bone
marrow
transplant
cytomegaloviru
common
viral
pathogen
varicella
zoster
viru
reactiv
occur
patient
hematopoiet
stem
cell
transplant
earli
seri
report
incid
rang
unusu
infect
present
dissemin
form
patient
pneumonia
one
complic
epidemiolog
hospitalacquir
viral
respiratori
infect
tradit
hospitalacquir
respiratori
viral
infect
thought
limit
immunocompromis
patient
howev
known
also
commonli
occur
immunocompet
patient
highlight
prospect
cohort
studi
includ
patient
hospitalacquir
pneumonia
proport
viral
infect
immunocompromis
patient
nonimmunocompromis
patient
identifi
virus
respiratori
syncyti
viru
parainfluenza
viru
influenza
viru
cytomegaloviru
human
coronaviru
bocaviru
human
metapneumoviru
adenoviru
data
underscor
import
infect
control
measur
patient
pneumonia
major
outbreak
atyp
pneumonia
report
case
initi
cluster
china
subsequ
report
worldwid
pneumonia
often
result
acut
respiratori
failur
name
sever
acut
respiratori
syndrom
subsequ
etiolog
agent
diseas
identifi
novel
coronaviru
name
urbani
strain
sever
acut
respiratori
syndromeassoci
coronaviru
anoth
novel
coronaviru
isol
patient
pneumonia
saudi
arabia
viru
subsequ
name
middl
east
respiratori
syndrom
coronaviru
infect
viru
caus
ill
clinic
similar
caus
sever
acut
respiratori
syndromeassoci
coronaviru
higher
mortal
case
middl
east
respiratori
syndrom
coronaviru
initi
report
saudi
arabia
subsequ
report
countri
includ
unit
state
typic
person
travel
arabian
peninsula
influenza
incid
influenza
vari
substanti
differ
season
exampl
use
onlin
surveil
data
estim
influenza
attack
rate
adult
age
year
old
ci
season
ci
season
rate
influenzaassoci
hospit
per
person
vari
differ
season
unit
state
differ
studi
show
approxim
onethird
hospit
patient
laboratoryconfirm
influenza
pneumonia
studi
includ
patient
hospit
influenza
pneumonia
older
influenza
season
attribut
mortal
pneumonia
influenza
unit
state
rang
cohort
studi
includ
laboratoryconfirm
case
influenza
admit
hospit
pneumonia
compar
without
pneumonia
like
requir
intens
care
unit
icu
admiss
vs
mechan
ventil
vs
die
vs
fig
older
subject
burden
respiratori
syncyti
viru
infect
similar
influenza
studi
prospect
follow
outpati
cohort
season
heathi
elderli
patient
highrisk
adult
highrisk
statu
defin
presenc
congest
heart
failur
chronic
pulmonari
diseas
respiratori
syncyti
viru
infect
diagnos
healthi
elderli
subject
highrisk
subject
account
respiratori
syncyti
viru
infect
per
personmonth
highrisk
adult
healthi
elderli
subject
analysi
hospit
viral
surveil
data
encompass
sever
year
estim
respiratori
syncyti
virusassoci
hospit
rate
per
personyear
unit
state
ci
patient
age
year
old
ci
patient
age
year
old
contrast
influenzaassoci
hospit
rate
respiratori
syncyti
virusassoci
hospit
rel
similar
across
year
cohort
hospit
adult
older
year
underli
cardiopulmonari
diseas
respiratori
syncyti
viru
infect
diagnos
patient
depend
year
hospit
patient
respiratori
syncyti
viru
infect
infiltr
chest
radiograph
requir
icu
admiss
requir
mechan
ventil
die
common
caus
common
cold
selflimit
acut
ill
occur
time
per
year
adult
infect
character
sneez
nasal
discharg
sore
throat
lowgrad
fever
rhinoviru
tend
occur
often
earli
fall
spring
rhinoviru
commonli
identifi
upper
respiratori
tract
patient
communityacquir
pneumonia
via
molecular
techniqu
fact
rhinoviru
commonli
identifi
pathogen
larg
cohort
adult
patient
hospit
communityacquir
pneumonia
conduct
unit
state
occur
commonli
winter
follow
season
pattern
resembl
influenza
coronavirus
ubiquit
circul
usual
etiolog
common
cold
coronavirus
also
commonli
associ
lower
respiratori
tract
symptom
adult
hospit
patient
coronaviru
infect
often
immunocompromis
pneumonia
common
occurr
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
caus
outbreak
pandem
acut
respiratori
ill
often
lead
respiratori
failur
adenoviru
common
caus
upper
respiratori
tract
symptom
conjunct
adult
patient
adenoviru
pneumonia
rel
young
differ
studi
report
patient
communityacquir
pneumonia
adenoviru
infect
mean
age
rang
year
old
adenoviru
also
caus
seriou
infect
immunocompromis
patient
adenoviru
speci
found
immunocompromis
patient
typic
found
commun
indic
endogen
viral
reactiv
patient
clear
season
although
case
may
spike
month
number
outbreak
caus
adenoviru
report
exampl
includ
report
outbreak
militari
personnel
psychiatr
care
facil
icu
parainfluenza
infect
caus
parainfluenza
parainfluenza
less
commonli
identifi
parainfluenza
rare
caus
respiratori
infect
adult
influenzalik
symptom
common
manifest
parainfluenza
infect
children
common
present
croup
bronchiol
populationbas
studi
adult
hospit
lower
respiratori
tract
infect
counti
ohio
detect
test
patient
epidem
season
span
summerautumn
epidem
season
span
springsumm
median
age
year
patient
year
patient
infect
infiltr
chest
radiograph
requir
icu
stay
none
die
identifi
acut
respiratori
ill
adult
prospect
follow
outpati
identifi
patient
communityacquir
pneumonia
among
outpati
adult
younger
age
tend
commonli
infect
metapneumoviru
presum
attribut
closer
contact
children
howev
hospit
patient
metapneumoviru
infect
older
mean
age
seri
communityacquir
pneumonia
metapneumoviru
infect
year
outpati
set
cough
nasal
congest
common
symptom
patient
metapneumoviru
infect
pneumonia
common
symptom
cough
sputum
product
dyspnea
fatigu
commonli
identifi
symptomat
asymptomat
children
seem
less
common
caus
respiratori
symptom
adult
human
bocaviru
infect
common
winter
common
clinic
present
includ
upper
respiratori
tract
symptom
bronchiol
pneumonia
case
enceph
report
detect
acut
respiratori
ill
adult
immunosuppress
chronic
lung
diseas
studi
show
often
identifi
sinu
tissu
specimen
adult
patient
chronic
sinus
patient
influenza
infect
gener
pneumonia
commonli
present
cough
fever
fatigu
myalgia
runni
nose
sweat
wheez
symptom
occur
close
half
patient
patient
influenza
pneumonia
tend
symptom
patient
nonpneumon
influenza
infect
import
distinct
patient
pneumonia
often
dyspnea
perhap
greatest
clinic
clue
influenza
patient
acut
respiratori
symptom
pneumonia
whether
patient
present
influenza
epidem
exampl
absenc
cough
temperatur
higher
c
make
influenza
unlik
patient
present
influenzalik
ill
outsid
influenza
epidem
lesser
impact
likelihood
influenza
patient
present
epidem
hand
presenc
symptom
epidem
substanti
increas
probabl
influenza
lesser
impact
outsid
epidem
studi
assess
accuraci
clinic
manifest
diagnosi
influenza
patient
acut
respiratori
symptom
earlier
studi
limit
retrospect
design
lead
potenti
classif
bia
relianc
clinic
manifest
final
diagnosi
influenza
lead
incorpor
bia
recent
studi
use
prospect
design
viral
polymeras
chain
reaction
test
refer
standard
prospect
studi
enrol
patient
influenzalik
ill
present
differ
clinic
viral
polymeras
chain
reaction
test
use
diagnosi
influenza
accuraci
number
symptom
test
multivari
analysi
cough
temperatur
remain
signific
predictor
influenza
prospect
studi
patient
present
emerg
depart
acut
respiratori
symptom
symptom
inventori
influenza
polymeras
chain
reaction
test
appli
patient
use
polymeras
chain
reaction
test
refer
standard
accuraci
clinic
judgment
decis
rule
rapid
influenza
test
provid
presenc
cough
fever
posit
likelihood
ratio
neg
likelihood
ratio
prospect
studi
highrisk
patient
present
emerg
depart
acut
respiratori
ill
clinician
ask
whether
thought
patient
influenza
viral
polymeras
chain
reaction
refer
standard
clinician
diagnosi
influenza
posit
likelihood
ratio
neg
likelihood
ratio
likelihood
ratio
interest
way
provid
accuraci
symptom
clinic
diagnosi
allow
estim
probabl
diseas
take
account
pretest
probabl
fig
see
tabl
summari
studi
overal
previous
describ
studi
indic
predict
valu
symptom
combin
symptom
clinic
impress
diagnosi
influenza
modest
patient
present
acut
ill
symptom
clinic
impress
enough
rule
rule
influenza
fact
clinician
fail
clinic
diagnos
influenza
approxim
twothird
influenzaconfirm
patient
prospect
seri
ultim
clinician
need
pay
close
attent
surveil
data
evid
influenza
activ
area
practic
acut
febril
respiratori
ill
place
influenza
high
possibl
differenti
diagnosi
unit
state
center
diseas
control
prevent
provid
weekli
data
influenza
activ
accord
region
countri
avail
http
wwwcdcgovfluweeklyindexhtm
import
aspect
clinic
histori
includ
close
contact
person
acut
febril
ill
recent
travel
addit
import
realiz
tropic
countri
influenza
circul
throughout
year
hallmark
respiratori
syncyti
viru
infect
presenc
wheez
occur
higher
frequenc
compar
patient
influenza
hospit
patient
respiratori
syncyti
viru
infect
may
present
clinicalradiolog
dissoci
patient
may
appear
toxem
despit
mild
radiolog
abnorm
cohort
hospit
patient
respiratori
syncyti
viru
infect
common
symptom
cough
dyspnea
wheez
nasal
congest
physic
examin
wheez
present
patient
temperatur
higher
c
present
patient
note
howev
percentag
hospit
patient
respiratori
syncyti
viru
infect
assess
hospit
patient
respiratori
syncyti
viru
infect
pneumonia
wheez
nasal
congest
less
common
anoth
studi
patient
respiratori
syncyti
viru
infect
clinic
diagnosi
pneumonia
common
symptom
cough
dyspnea
wheez
fever
runni
nose
physic
examin
common
find
wheez
rhonchi
crackl
pneumonia
caus
influenza
respiratori
syncyti
viru
specif
clinic
manifest
pneumonia
caus
respiratori
virus
fact
symptom
sign
specif
enough
differenti
viral
bacteri
pneumonia
usual
clinic
manifest
pneumonia
includ
fever
higher
c
heart
rate
faster
beat
per
minut
crackl
decreas
breath
sound
expect
pneumonia
caus
respiratori
virus
end
diagnosi
viral
infect
patient
pneumonia
reli
recognit
respiratori
virus
common
etiolog
pneumonia
systemat
perform
viral
microbiolog
studi
patient
chest
radiograph
patient
viral
pneumonia
show
differ
pattern
includ
groundglass
opac
consolid
nodular
opac
gener
patient
present
faint
opac
commonli
describ
groundglass
pattern
second
commonli
report
pattern
consolid
nodular
opac
less
common
occur
opac
often
patchi
distribut
bilater
involv
fairli
common
seri
influenza
pneumonia
show
bilater
involv
slightli
common
unilater
involv
hand
seri
respiratori
syncyti
viru
coronaviru
pneumonia
show
unilater
involv
common
pleural
effus
usual
report
comput
tomographi
chest
common
pattern
groundglass
opac
becom
even
notic
often
patchi
bilater
distribut
pattern
consolid
nodular
opac
interlobular
thicken
also
present
fig
similar
clinic
manifest
radiolog
find
specif
allow
differenti
viral
bacteri
infect
patient
pneumonia
let
alon
identif
specif
viru
radiolog
find
howev
help
corrobor
diagnosi
viral
pneumonia
instanc
patient
viral
pathogen
identifi
oropharyng
swab
demonstr
patchi
groundglass
opac
lung
suggest
viral
pneumon
infiltr
main
class
antivir
drug
treatment
influenza
includ
neuraminidas
inhibitor
adamantan
influenza
virus
infect
cell
bind
surfac
glycoprotein
hemagglutinin
sialic
acid
receptor
attach
viru
releas
cell
anoth
surfac
glycoprotein
neuraminidas
target
neuraminidas
inhibitor
adamantan
includ
amantadin
rimantadin
block
protein
membran
protein
ion
channel
activ
exhibit
activ
influenza
influenza
b
antivir
drug
current
approv
us
food
drug
administr
neuraminidas
inhibitor
oral
oseltamivir
inhal
zanamivir
intraven
peramivir
adamantan
recommend
treatment
influenza
high
resist
influenza
drug
number
clinic
trial
assess
effect
oseltamivir
influenza
comprehens
systemat
review
summar
effect
oseltamivir
prophylaxi
treatment
adult
children
assess
time
allevi
symptom
adult
influenza
studi
pool
total
patient
oseltamivir
group
placebo
group
oseltamivir
led
earlier
relief
symptom
hour
ci
hour
p
assess
pneumonia
prevent
adult
influenza
studi
pool
includ
patient
oseltamivir
group
placebo
group
oseltamivir
led
reduct
pneumonia
risk
differ
assess
hospit
prevent
adult
influenza
studi
pool
includ
patient
oseltamivir
group
placebo
group
differ
need
hospit
risk
ratio
ci
p
pool
studi
adult
includ
patient
oseltamivir
group
control
group
show
oseltamivir
led
nausea
risk
ratio
ci
p
vomit
risk
ratio
ci
p
aggreg
metaanalys
indic
influenzainfect
patient
treat
oseltamivir
modest
benefit
relief
symptom
prevent
pneumonia
come
expens
nausea
vomit
note
howev
patient
includ
trial
appear
ill
instanc
studi
enrol
patient
immunosuppress
condit
human
immunodefici
viru
infect
malign
includ
metaanalys
inclus
criteria
pool
studi
presenc
influenzalik
ill
rather
pneumonia
addit
death
report
among
trial
includ
adult
popul
earlier
systemat
review
includ
observ
studi
evalu
antivir
therapi
versu
therapi
antivir
therapi
patient
laboratoryconfirm
clinic
diagnosi
influenza
review
observ
studi
import
distinct
review
random
clinic
trial
first
investig
pool
studi
includ
hospit
patient
highrisk
popul
pool
studi
total
patient
adjust
confound
show
oseltamivir
compar
antivir
therapi
associ
reduct
mortal
ci
qualiti
evid
gener
review
gener
low
reli
observ
studi
risk
confound
despit
adjust
analys
howev
observ
studi
metaanalys
fill
import
knowledg
gap
like
address
clinic
trial
center
diseas
control
prevent
recommend
treatment
initi
soon
possibl
hospit
patient
sever
complic
progress
diseas
higher
risk
influenza
complic
agre
center
diseas
control
prevent
recommend
submit
influenzainfect
patient
pneumonia
complic
influenza
receiv
antivir
therapi
current
neuraminidas
inhibitor
absenc
sensit
pointofcar
polymeras
chain
reaction
clinician
decid
whether
initi
empir
treatment
influenza
pneumonia
strong
consider
given
surveil
data
risk
factor
influenza
import
note
influenza
diagnosi
often
miss
also
clinician
often
fail
prescrib
antivir
influenza
treatment
clinic
diagnosi
influenza
made
indic
treatment
benefit
treatment
greatest
start
earli
surviv
benefit
demonstr
treatment
day
symptom
initi
fig
treatment
pneumonia
caus
respiratori
virus
influenza
defin
whether
patient
immunocompet
immunosuppress
import
immunocompet
patient
current
antivir
treatment
option
limit
gener
reserv
sever
ill
patient
base
anecdot
data
instanc
case
report
seri
report
use
cidofovir
treatment
sever
pneumonia
caus
adenoviru
nonimmunocompromis
patient
even
though
patient
clinic
improv
seri
studi
uncontrol
thu
allow
firm
conclus
efficaci
cidofovir
antivir
treatment
pneumonia
caus
virus
herpesvirida
famili
immunocompet
host
report
sever
case
pregnant
women
varicella
zoster
viru
pneumonia
mortal
high
treatment
intraven
acyclovir
indic
immunosuppress
patient
aerosol
ribavirin
oral
ribavirin
intraven
immunoglobulin
hyperimmunoglobulin
palivizumab
treatment
option
use
respiratori
syncyti
viru
infect
particularli
patient
hematolog
malign
transplant
recipi
cytomegaloviru
pneumonia
treatment
includ
intraven
ganciclovir
addit
cytomegaloviru
immunoglobulin
ganciclovir
appear
lead
improv
surviv
accord
case
seri
altern
treatment
cytomegaloviru
pneumonia
intraven
foscarnet
treatment
varicella
pneumonia
indic
treatment
intraven
acyclovir
similarli
herp
simplex
viru
pneumonia
treat
intraven
acyclovir
evid
use
therapi
weak
come
form
observ
studi
fig
identif
viral
pathogen
pneumonia
prompt
clinician
discontinu
initi
empir
antibiot
dual
bacterialvir
infect
common
fact
recognit
dual
bacterialvir
common
seem
reflect
clinic
practic
observ
studi
patient
respiratori
tract
infect
admit
hospit
turn
identifi
viral
pathogen
antibiot
discontinu
hand
use
clinic
pathway
integr
result
viral
microbiolog
test
clinic
find
procalcitonin
test
could
role
safe
discontinu
antibiot
well
establish
use
procalcitonin
guid
initi
discontinu
antibiot
patient
acut
respiratori
tract
infect
lead
less
use
antibiot
without
worsen
outcom
random
clinic
trial
hospit
patient
lower
respiratori
tract
infect
use
combin
procalcitonin
viral
polymeras
chain
reaction
test
compar
standard
care
group
similar
antibiot
exposur
howev
lower
proport
patient
posit
viral
polymeras
chain
reaction
test
low
procalcitonin
receiv
antibiot
discharg
compar
standard
care
studi
suggest
result
viral
polymeras
chain
reaction
test
impact
influenc
decis
make
even
procalcitonin
clinic
evolut
factor
note
howev
feasibl
studi
patient
pneumonia
exclud
addit
viral
polymeras
chain
reaction
test
result
may
influenc
antibiot
decis
absenc
protocol
shown
observ
retrospect
studi
patient
antibiot
discontinu
within
hour
posit
viral
respiratori
panel
low
procalcitonin
result
anoth
random
clinic
trial
assess
effect
pointofcar
respiratori
viral
panel
patient
acut
respiratori
ill
fever
studi
enrol
patient
differ
primari
endpoint
proport
patient
treat
antibiot
howev
relev
primari
outcom
impair
mani
patient
receiv
antibiot
result
pointofcar
test
significantli
greater
proport
patient
pointofcar
group
receiv
singl
dose
antibiot
vs
antibiot
less
hour
vs
summari
weak
mount
evid
use
nucleic
acid
amplif
test
potenti
aid
decis
discontinu
antibiot
patient
respiratori
infect
includ
pneumonia
like
integr
clinic
find
procalcitonin
addit
continu
clinician
educ
import
ensur
implement
strategi
minim
antibiot
exposur
exuber
inflammatori
respons
play
major
role
morbid
mortal
patient
pneumonia
corticosteroid
use
way
mitig
exacerb
inflammatori
respons
patient
systemat
review
synthes
result
clinic
trial
assess
system
corticosteroid
clinic
trial
mostli
small
sampl
size
rang
patient
although
statist
signific
improv
mortal
observ
gener
corticosteroid
led
reduct
mortal
patient
sever
communityacquir
pneumonia
risk
ratio
ci
corticosteroid
may
particularli
benefici
patient
communityacquir
pneumonia
heighten
inflammatori
state
demonstr
trial
enrol
patient
sever
communityacquir
pneumonia
creactiv
protein
greater
mgl
summari
despit
small
sampl
size
trial
weight
evid
current
favor
use
system
corticosteroid
patient
communityacquir
pneumonia
admit
hospit
particularli
patient
high
inflammatori
state
sever
pneumonia
approach
current
reserv
use
corticosteroid
patient
communityacquir
pneumonia
creactiv
protein
greater
mgl
lactic
acid
greater
nmoll
acidosi
ph
pandem
brought
light
use
system
corticosteroid
influenza
pneumonia
studi
reveal
patient
sever
influenza
pneumonia
receiv
corticosteroid
pandem
unfortun
although
corticosteroid
appear
benefici
patient
sever
communityacquir
pneumonia
hold
true
patient
influenza
pneumonia
condit
corticosteroid
may
actual
detriment
demonstr
systemat
review
studi
investig
pool
observ
studi
total
patient
found
corticosteroid
therapi
associ
higher
odd
death
ci
note
studi
includ
metaanalysi
predominantli
conduct
influenza
pandem
icu
set
clinic
trial
design
evalu
effect
system
corticosteroid
icu
patient
influenza
pneumonia
unabl
enrol
plan
number
patient
highlight
difficulti
conduct
clinic
trial
pandem
limit
observ
studi
assess
corticosteroid
therapi
influenza
pneumonia
possibl
confound
indic
possibl
sicker
patient
often
prescrib
system
corticosteroid
potenti
caus
fals
impress
corticosteroid
therapi
lead
wors
outcom
influenza
pneumonia
studi
adjust
confound
factor
residu
confound
still
occur
absenc
random
clinic
trial
view
result
observ
studi
opinion
current
corticosteroid
therapi
administ
influenza
pneumonia
effect
corticosteroid
patient
noninfluenza
viral
pneumonia
unclear
advent
nucleic
acid
amplif
test
improv
understand
epidemiolog
viral
infect
pneumonia
enabl
etiolog
diagnosi
viral
infect
larg
proport
patient
pneumonia
howev
one
downsid
nucleic
acid
amplif
test
rel
long
turnaround
limit
clinic
util
overcom
develop
pointofcar
polymeras
chain
reaction
test
turnaround
time
approxim
hour
assess
pointofcar
test
clinic
pathway
promis
venu
clinic
investig
test
rapidli
integr
clinic
practic
import
studi
costeffect
whether
influenc
outcom
decis
make
ongo
research
antivir
treatment
promis
bacteri
infect
combin
therapi
studi
influenza
infect
differ
goal
prevent
pathogen
resist
mitig
inflammatori
respons
achiev
synergi
develop
new
compound
treatment
respiratori
syncyti
viru
includ
fusion
inhibitor
prevent
fusion
respiratori
syncyti
viru
viral
envelop
host
cell
membran
nucleosid
analog
prevent
respiratori
syncyti
viru
replic
summari
viral
respiratori
infect
common
pneumonia
present
approxim
patient
communityacquir
pneumonia
also
common
immunosuppress
patient
latter
suscept
usual
communityacquir
respiratori
virus
also
virus
herpesvirida
famili
recent
data
show
respiratori
virus
also
identifi
hospitalacquir
infect
clinic
diagnosi
viral
infect
challeng
clinic
predict
rule
develop
diagnosi
influenza
infect
show
modest
accuraci
similarli
radiolog
studi
nonspecif
end
diagnosi
viral
infect
reli
recognit
respiratori
virus
commonli
present
pneumonia
systemat
perform
viral
microbiolog
studi
particularli
nucleic
acid
amplif
test
treatment
influenza
pneumonia
current
neuraminidas
inhibitor
treatment
option
pneumonia
caus
virus
immunocompet
patient
pneumonia
limit
data
larg
anecdot
immunosuppress
patient
infect
respiratori
syncyti
viru
viru
herpesvirida
famili
antivir
treatment
avail
ongo
research
involv
develop
test
new
treatment
strategi
influenza
noninfluenza
virus
